Evidence map›Paper›PMID 37556376›Full record

Observational studyDrug and alcohol review2023

Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study.

Steven Hobday, Heather Valerio, Troy Combo, Robert Monaghan, Clarke Scott, David Silk, Carolyn Murray, Phillip Read, Charles Henderson, Louisa Degenhardt and 5 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Drug and alcohol review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Steven HobdayThe Kirby Institute, University of New South Wales, Sydney, Australia.
Heather ValerioThe Kirby Institute, University of New South Wales, Sydney, Australia.ORCID 0000-0002-8608-2558
Troy ComboInfectious Disease Implementation Science Group, Burnet Institute, Melbourne, Australia.
Robert MonaghanThe Kirby Institute, University of New South Wales, Sydney, Australia.
Clarke ScottNepean Blue Mountains Local Health District, NSW Health, Penrith, Australia.
David SilkThe Kirby Institute, University of New South Wales, Sydney, Australia.
Carolyn MurrayPublic Health Programs, NSW Health, Sydney, Australia.
Phillip ReadThe Kirby Institute, University of New South Wales, Sydney, Australia.
Charles HendersonNSW Users and AIDS Association, Sydney, Australia.
Louisa DegenhardtNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-8513-2218
Carla TreloarCentre for Social Research in Health, University of New South Wales, Sydney, Australia.
Gregory J DoreThe Kirby Institute, University of New South Wales, Sydney, Australia.
Jason GrebelyThe Kirby Institute, University of New South Wales, Sydney, Australia.
Marianne MartinelloThe Kirby Institute, University of New South Wales, Sydney, Australia.
ETHOS Engage Study Group
UNSW Sydney · AUBurnet Institute · AUNational Association of People with HIV Australia · AUNepean Hospital · AUNew South Wales Department of Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEvaluating progress towards hepatitis C virus (HCV) elimination among Aboriginal and Torres Strait Islander peoples is critical given the disproportionate burden of infection. We examined factors associated with current HCV infection and self-reported treatment among Aboriginal and Torres Strait Islander (hereafter referred to as Aboriginal peoples) and non-Aboriginal peoples who inject drugs (PWID) in Australia.

methodsETHOS Engage is an observational cohort study of PWID attending drug treatment and needle and syringe programs in Australia. Participants underwent point-of-care HCV RNA testing (Xpert HCV RNA Viral Load Fingerstick) and completed a questionnaire including self-reported history of HCV treatment.

resultsBetween May 2018 and June 2021, 2395 participants were enrolled and 555 (23%) identified as Aboriginal (median age 42 years, 58% were men, 63% injected drugs in last month, 76% ever incarcerated). HCV RNA prevalence was 23% among Aboriginal PWID (24% in 2018-2019 and 21% in 2019-2021; p = 0.44), and 21% among non-Aboriginal PWID (24% in 2018-2019 and 16% in 2019-2021; p < 0.001). Self-reported HCV treatment was 65% among Aboriginal PWID (63% in 2018-2019 and 69% in 2019-2021; p = 0.30), and 70% among non-Aboriginal PWID (67% in 2018-2019 and 75% in 2019-2021; p < 0.001). Among Aboriginal PWID, current HCV infection was associated with recently injecting drugs and receiving opioid agonist treatment, and self-reported HCV treatment was negatively associated with younger age, homelessness and recently injecting drugs. DISCUSSION AND

conclusionsEquitable access to HCV care and prevention is needed to ensure Australia meets its elimination targets among Aboriginal PWID.

Indexed as

Hepatitis CSubstance Abuse, IntravenousAdultAustraliaAustralian Aboriginal and Torres Strait Islander PeoplesFemaleHepacivirusHumansMalePrevalenceRNARNAdirect acting antiviralseliminationHCVIndigenouspeople who inject drugs

Identifiers

PMID37556376
PMCPMC10946462
OpenAlexW4385690279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.